重组人脑利钠肽治疗充血性心力衰竭疗效评价.docVIP

重组人脑利钠肽治疗充血性心力衰竭疗效评价 　　[摘要] 目的 探析重组人脑利钠肽治疗充血性心力衰竭的临床疗效。 方法 随机选取该院2013年1月―2014年12月收治的120例充血性心力衰竭患者，回顾性分析其临床资料，在患者知情同意的情况下将其分为治疗组和对照组，治疗组采取重组人脑利钠肽进行治疗，对照组采取常规的治疗方法，对比分析两组患者的治疗效果。结果 治疗前后两组患者的LVWP、LVD、HR显著降低，LVEF显著升高，治疗组患者的LVWP、LVD、HR及LVEF较对照组比较差异有统计学意义（P0.05）；治疗组患者总有效率为91.67%较对照组66.67%差异具有统计学意义（P0.05）；治疗组患者不良反应发生率为3.33%较对照组8.34%，差异有统计学意义（P0.05）。结论 重组人脑利钠肽治疗充血性心力衰竭的临床疗效显著，不良反应少，有效率高，安全性好，值得应用。 　　[关键词] 重组人脑利钠肽；充血性心力衰竭；临床疗效 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2015）04（c）-0091-02 　　[Abstract] Objective To explore the clinical effect of recombinant human brain natriuretie peptide（rhBNP） on congestive heart failure. Methods Our hospital in January 2013 -2014 December treated 120 cases of congestive heart failure patients， a retrospective analysis of the clinical data， in the case of patients with informed consent will be divided into a treatment group and the control group， the treatment group received recombinant human brain natriuretic peptide treatment， the control group received conventional treatment methods， comparative analysis of the two groups of patients with the therapeutic effect. Results Two groups of patients before and after treatment LVWP， LVD， HR was significantly lower， LVEF significantly higher in patients treated with LVWP， LVD， HR and LVEF than in the control group were significantly different， P 0.05 statistically significant； there are always treated patients efficiency91.67% compared with the control group 66.67% difference was significant， P0.05 statistically significant； adverse reactions in patients treated with incidence3.33% compared with the control group8.34% difference was significant， P 0.05 considered statistically significant. Conclusion The clinical efficacy of recombinant human brain natriuretic peptide treatment of congestive heart failure was significantly less adverse reactions， high efficiency， safety， deserve applications. 　　[Key words] Recombinant human brain natriuretic peptid； Congestive heart failure； Clinical efficacy